Sorrento Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2006-01-01
- Employees
- 949
- Market Cap
- -
An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT05692908
Study to Access Anti-CD38 Anibody Drug in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-10-18
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT05584709
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Long-Term Follow-Up of Patients Who Received Gene-Modified Cell Therapy
- Conditions
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT05472649
- Locations
- 🇺🇸
Abramson Cancer Center Clinical Research Unit, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Study to Evaluate the Efficacy of IN STI-9199 in Treating Symptomatic COVID-19 in Outpatient Adults and Adolescents
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT05372783
- Locations
- 🇺🇸
ProSciento, Inc., Chula Vista, California, United States
Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT05364840
- Locations
- 🇦🇺
Scientia Clinical Research Ltd, Randwick, New South Wales, Australia
Study to Assess the Safety and Preliminary Efficacy of STI-1386 Oncolytic Virus in Relapsed or Refractory Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05361954
Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05361915
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸UCSD Moores Cancer Center, La Jolla, California, United States
Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT05308225
- Locations
- 🇺🇸
NYU Lagone Health, New York, New York, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection
- First Posted Date
- 2021-10-12
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Registration Number
- NCT05074394
Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Sorrento Therapeutics, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05067257
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Altman Clinical and Translational Research Institute (ACTRI), La Jolla, California, United States